Literature DB >> 18206533

Specific clones of spontaneously evolving karyotypes generate individuality of cancers.

Alice Fabarius1, Ruhong Li, George Yerganian, Ruediger Hehlmann, Peter Duesberg.   

Abstract

Several researchers, including us, have recently proposed that specific karyotypes, rather than specific mutations, generate the "biochemical individuality" of cancers, defined by individual growth rates, metabolisms, drug-resistances, metastases and cell morphologies. According to our theory, independent karyotypic evolutions generate cancers, much like new phylogenetic species. To allow such evolutions in the lifetime of an organism, the normal karyotype must be destabilized, but not the genes. The karyotype is destabilized by aneuploidy, because aneuploidy unbalances conserved teams of proteins that segregate, synthesize and repair chromosomes. And aneuploidy is induced either by carcinogens or spontaneously. Here, we tested this theory using a new system that virtually excludes spontaneous mutation. In this sytem, 50% of normal human muscle cells became aneuploid and 5 per 10(6) formed foci of transformed Mu6 cells - only 2 months after transfection with 6 virus-activated cellular genes. Analyses of 10 foci revealed: (1) clonal karyotypes, consisting of one or more stemlines of spontaneously evolving aneuploidies and some non-clonal aneuploidies, and (2) individual phenotypes, such as cell morphologies, growth rates and intrinsic resistance to cytosine arabinoside, shared by 5 foci with a common stemline. Due to the short preneoplastic latencies of Mu6 cells several non-clonal precursors of focus-specific, aneuploid karyotypes were detectable before focus formation. Chemical carcinogens were also found to induce tumors with clonally evolving stemlines in Chinese hamsters. We conclude that specific clones of spontaneously evolving karyotypes, rather than specific mutations, generate the individuality of cancers. This answers the age-old question, why even cancers of the same kind do not have consistent karyotypes.

Entities:  

Mesh:

Year:  2008        PMID: 18206533     DOI: 10.1016/j.cancergencyto.2007.10.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Authors:  Javier A Menendez; Tomás Alarcón; Bruna Corominas-Faja; Elisabet Cuyàs; Eugeni López-Bonet; Angel G Martin; Luciano Vellon
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

2.  Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.

Authors:  Sureyya Bozkurt; Burak Uz; Yahya Buyukasik; Ozlen Bektas; Ayten Inanc; Hakan Goker; Emin Kansu
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

3.  Speciation Theory of Carcinogenesis Explains Karyotypic Individuality and Long Latencies of Cancers.

Authors:  Ankit Hirpara; Mathew Bloomfield; Peter Duesberg
Journal:  Genes (Basel)       Date:  2018-08-09       Impact factor: 4.096

4.  GIN'n'CIN hypothesis of brain aging: deciphering the role of somatic genetic instabilities and neural aneuploidy during ontogeny.

Authors:  Yuri B Yurov; Svetlana G Vorsanova; Ivan Y Iourov
Journal:  Mol Cytogenet       Date:  2009-11-25       Impact factor: 2.009

5.  Immortality of cancers: a consequence of inherent karyotypic variations and selections for autonomy.

Authors:  Peter Duesberg; Amanda McCormack
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

6.  Nuclear DNA-Content in Mesenchymal Lesions in Dogs: Its Value as Marker of Malignancy and Extent of Genomic Instability.

Authors:  Kim M Boerkamp; Gerard R Rutteman; Marja J L Kik; Jolle Kirpensteijn; Christoph Schulze; Guy C M Grinwis
Journal:  Cancers (Basel)       Date:  2012-12-03       Impact factor: 6.639

7.  Karyotype alteration generates the neoplastic phenotypes of SV40-infected human and rodent cells.

Authors:  Mathew Bloomfield; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2015-10-22       Impact factor: 2.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.